Literature DB >> 23323151

Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.

Daniel I G Cubero1, Auro Del Giglio.   

Abstract

Entities:  

Year:  2013        PMID： 23323151      PMCID： PMC3539279          DOI： 10.1177/1758834012469430

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  9 in total

1.  Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

Authors:  Maarten J Deenen; Wim E Terpstra; Annemieke Cats; Henk Boot; Jan H M Schellens
Journal:  Ann Intern Med       Date:  2010-12-07       Impact factor: 25.391

2.  Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

Authors:  Z Lu; R Zhang; J T Carpenter; R B Diasio
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

3.  Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.

Authors:  Lori Kay Mattison; Jeanne Fourie; Renee A Desmond; Anil Modak; Muhammad Wasif Saif; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

4.  Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.

Authors:  Daniel I G Cubero; Felipe Melo Cruz; Patrícia Santi; Ismael Dale C G Silva; Auro Del Giglio
Journal:  Ther Adv Med Oncol       Date:  2012-07       Impact factor: 8.168

5.  Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

6.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

Authors:  Jean-Yves Douillard; Paulo M Hoff; Jamey R Skillings; Peter Eisenberg; Neville Davidson; Peter Harper; Mark D Vincent; Barry C Lembersky; Seth Thompson; Antonella Maniero; Steven E Benner
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

8.  Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

Authors:  James Carmichael; Tadeusz Popiela; David Radstone; Stephen Falk; Markus Borner; Amit Oza; Torben Skovsgaard; Stephane Munier; Christophe Martin
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

9.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Authors:  Z Lu; R Zhang; R B Diasio
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701
  9 in total
  2 in total

Review 1.  The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.

Authors:  Xiaojun Sun; Shilei Guo
Journal:  Pathol Oncol Res       Date:  2018-12-05       Impact factor: 3.201

Review 2.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.